ReviewJournal of industrial microbiology & biotechnology2012
Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.
Review in Journal of industrial microbiology & biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
146 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recombinant expression of insoluble enzymes in Escherichia coli: a systematic review of experimental design and its manufacturing implications.Microbial cell factories · 2021Pooled it
- UniSePT: an engineered broadly applicable Unique Secretory signal PepTide for high-yield biotherapeutic production in mammalian cell-based expression systems.Journal of biological engineering · 2026Article
- Heterologous expression of lipase gene in Cereibacter sphaeroides 2.4.1 driven by an anaerobic Photosynthesis-Inducible promoter.Journal, genetic engineering & biotechnology · 2026Article
- Enhancing the E. coli Cell Density Expressing the Recombinant Cellulolytic Chimeric Enzyme from Acetivibrio thermocellus by Statistical Optimization of the Medium.Current microbiology · 2026Article
- Article
- Circular Approach to Biomanufacturing: Enhancing Therapeutic Protein Production Using Chum Salmon Head Peptone.Bioengineering (Basel, Switzerland) · 2026Article
- Escherichia coli BL21 adapts its central carbon metabolism to recombinant protein production and oxygen limitation.Microbial cell factories · 2026Article
- Kinetic modeling of terpenoid production in E. coli: insights into subpopulation emergence and process optimization.Microbial cell factories · 2025Article
- Recombinant L-asparaginase from Stenotrophomonas maltophilia: a promising low-immunogenic anticancer agent.Microbial cell factories · 2025Article
- Exploring an Aptamer-Based Approach to Assess Canine Parvovirus Integrity After Disinfection Treatment.Viruses · 2025Article
- A Minimalist Model Lipid System Mimicking the Biophysical Properties ofLangmuir : the ACS journal of surfaces and colloids · 2025Article
- Syphilis vaccine development: Aligning vaccine design with manufacturing requirements.Human vaccines & immunotherapeutics · 2024Article
- Modifications of the 5' region of the CASPONMicrobial cell factories · 2024Article
- Evaluation of Cellular Responses of HeterotrophicMicroorganisms · 2024Article
- An Efficient Expression and Purification Protocol for SpCas9 Nuclease and Evaluation of Different Delivery Methods of Ribonucleoprotein.International journal of molecular sciences · 2024Article
- Genetically modified chickens as bioreactors for protein-based drugs.Frontiers in genome editing · 2024Review
- Designing a Secretory form of RTX-A as an Anticancer Toxin: AnRecent patents on biotechnology · 2024Article
- A synthetic methylotrophicNature catalysis · 2024Article
- Production of recombinant lumpy skin disease virus A27L and L1R proteins for application in diagnostics and vaccine development.Vaccine: X · 2023Article
- Cloning, Expression and Functional Characterization of a Novel α-Humulene Synthase, Responsible for the Formation of Sesquiterpene in Agarwood Originating fromCurrent issues in molecular biology · 2023Article
86 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nearly 30% of currently approved recombinant therapeutic proteins are produced in Escherichia coli. Due to its well-characterized genetics, rapid growth and high-yield production, E. coli has been a preferred choice and a workhorse for expression of non-glycosylated proteins in the biotech industry. There is a wealth of knowledge and comprehensive tools for E. coli systems, such as expression vectors, production strains, protein folding and fermentation technologies, that are well tailored for industrial applications. Advancement of the systems continues to meet the current industry needs, which are best illustrated by the recent drug approval of E. coli produced antibody fragments and Fc-fusion proteins by the FDA. Even more, recent progress in expression of complex proteins such as full-length aglycosylated antibodies, novel strain engineering, bacterial N-glycosylation and cell-free systems further suggests that complex proteins and humanized glycoproteins may be produced in E. coli in large quantities. This review summarizes the current technology used for commercial production of recombinant therapeutics in E. coli and recent advances that can potentially expand the use of this system toward more sophisticated protein therapeutics.
Indexed as
Identifiers
22252444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.